Stockreport

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor c [Read more]